Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104165 | 1.00 | GRM5 (0.70) | GRM5NPSR1LMNAALDH1A1TP53 | |
| SCHEMBL3106141 | 0.92 | GRM5 (0.70) | GRM5NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3106160 | 0.92 | GRM5 (0.70) | GRM5NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3110795 | 0.87 | GRM5 (0.59) | GRM5NPSR1LMNAALDH1A1TP53 | |
| SCHEMBL3110804 | 0.87 | GRM5 (0.59) | GRM5NPSR1LMNAALDH1A1TP53 | |
| SCHEMBL3110978 | 0.83 | GRM5 (0.47) | GRM5NPSR1LMNAALDH1A1TP53 | |
| SCHEMBL3110972 | 0.83 | GRM5 (0.47) | GRM5NPSR1LMNAALDH1A1TP53 | |
| SCHEMBL2958268 | 0.82 | GRM5 (1.00) | GRM5POLBMAPK14 | |
| SCHEMBL2889757 | 0.82 | GRM5 (0.46) | GRM5LMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2895011 | 0.79 | ALOX12 (0.48) | GRM5NPSR1LMNAALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | claimed |
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | GRM5, GRM3, GRIK5 | GRM5 1/4885NPSR1 189/4885LMNA 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.